GB1561358A - Diagnostic reagent for carrying out uric acid assays on blood and urine samples - Google Patents
Diagnostic reagent for carrying out uric acid assays on blood and urine samples Download PDFInfo
- Publication number
- GB1561358A GB1561358A GB35054/76A GB3505476A GB1561358A GB 1561358 A GB1561358 A GB 1561358A GB 35054/76 A GB35054/76 A GB 35054/76A GB 3505476 A GB3505476 A GB 3505476A GB 1561358 A GB1561358 A GB 1561358A
- Authority
- GB
- United Kingdom
- Prior art keywords
- uric acid
- adenine
- guanine
- sample
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 17
- 210000002700 urine Anatomy 0.000 title claims description 8
- 210000004369 blood Anatomy 0.000 title claims description 5
- 239000008280 blood Substances 0.000 title claims description 5
- 238000008114 Uric Acid Assay Methods 0.000 title description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 33
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 32
- 229940116269 uric acid Drugs 0.000 claims description 32
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 12
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 11
- 229930024421 Adenine Natural products 0.000 claims description 11
- 229960000643 adenine Drugs 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 201000005569 Gout Diseases 0.000 description 10
- 201000001431 Hyperuricemia Diseases 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229920002477 rna polymer Polymers 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 230000009858 acid secretion Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000003748 differential diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000007257 malfunction Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000004144 purine metabolism Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 101100165798 Arabidopsis thaliana CYP86A1 gene Proteins 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 150000001887 cortisones Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000004147 pyrimidine metabolism Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
- Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
- Y10T436/148888—Uric acid
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19752537488 DE2537488C2 (de) | 1975-08-22 | Mittel zur Durchführung eines Harnsäure-Belastungstests |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1561358A true GB1561358A (en) | 1980-02-20 |
Family
ID=5954641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB35054/76A Expired GB1561358A (en) | 1975-08-22 | 1976-08-23 | Diagnostic reagent for carrying out uric acid assays on blood and urine samples |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4101648A (enExample) |
| AT (1) | AT347602B (enExample) |
| CH (1) | CH619365A5 (enExample) |
| FR (1) | FR2321292A1 (enExample) |
| GB (1) | GB1561358A (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2263315C2 (ru) * | 2002-03-19 | 2005-10-27 | Нижегородский научно-исследовательский институт детской гастроэнтерологии | Способ дифференциальной диагностики обострения и ремиссии гастродуоденальных заболеваний у детей |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE757653A (fr) * | 1969-10-21 | 1971-04-16 | Ugine Kuhlmann | Nouveaux medicaments derives d'acides nucleiques et procedes pour leur preparation |
-
1976
- 1976-08-18 AT AT613776A patent/AT347602B/de not_active IP Right Cessation
- 1976-08-20 CH CH1062276A patent/CH619365A5/de not_active IP Right Cessation
- 1976-08-23 GB GB35054/76A patent/GB1561358A/en not_active Expired
- 1976-08-23 FR FR7625461A patent/FR2321292A1/fr active Granted
- 1976-08-23 US US05/716,549 patent/US4101648A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| FR2321292A1 (fr) | 1977-03-18 |
| CH619365A5 (enExample) | 1980-09-30 |
| ATA613776A (de) | 1978-05-15 |
| FR2321292B1 (enExample) | 1978-11-17 |
| DE2537488B1 (de) | 1976-03-25 |
| AT347602B (de) | 1979-01-10 |
| US4101648A (en) | 1978-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yuzbasiyan-Gurkan et al. | Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction | |
| Meltzer | Muscle enzyme release in the acute psychoses | |
| Waalkes et al. | The urinary excretion of nucleosides of ribonucleic acid by patients with advanced cancer | |
| Peng et al. | High-pressure liquid-chromatographic method for determination of gentamicin in plasma. | |
| Smith | Contribution of quantitative assay technics to the understanding of the clinical pharmacology of digitalis | |
| WO2008140814A1 (en) | Methods for detecting cardiac damage | |
| Mansell et al. | N-Acetyl-β-D-glucosaminidase: a new approach to the screening of hypertensive patients for renal disease | |
| WILLIAMS et al. | THIAMINE METABOLISM: WITH PARTICULAR REFERENCE TO THE ROLE OF THE LIVER AND KIDNEYS | |
| ROSENBAUM et al. | Diabetic and prediabetic nephropathy in childhood | |
| Bashir et al. | Methylmalonic acid excretion in vitamin B12 deficiency | |
| Witschy et al. | TRH-induced prolactin release is blunted in females with endogenous unipolar major depression | |
| Wangel et al. | A family study of pernicious anaemia: II. Intrinsic factor secretion, vitamin B12 absorption and genetic aspects of gastric autoimmunity | |
| Bolt et al. | A clinical evaluation of tubeless gastric analysis | |
| Donald, PR & Malan | Cerebrospinal fluid lactate and lactate dehydrogenase activity in the rapid diagnosis of bacterial meningitis | |
| GB1561358A (en) | Diagnostic reagent for carrying out uric acid assays on blood and urine samples | |
| Mitchell et al. | Renal function tests suitable for clinical practice | |
| Shum et al. | Effect of pH changes on the binding of vitamin B12 by intrinsic factor | |
| Turner et al. | AMINOACID EXCRETION IN INFANCY AND EARLY CHILDHOOD A SURVEY OF 100,000 INFANTS | |
| Phelps et al. | Effect of age and serum creatinine on endogenous digoxin-like substances in infants and children | |
| Goldberg et al. | Radioactive vitamin B12 studies: Experience with the urinary excretion test and the measurement of absorbed plasma radioactivity | |
| Lindgren et al. | Schilling and protein‐bound cobalamin absorption tests are poor instruments for diagnosing cobalamin malabsorption | |
| Shaw et al. | The determination of vitamin B12. A critical review | |
| US2794786A (en) | Thionin dye-ion exchange resin indicator compounds | |
| RABINER et al. | The urinary excretion test in the diagnosis of Addisonian pernicious anemia | |
| Moffat | Interpretation of post mortem serum levels of cardiac glycosides after suspected overdosage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| PCNP | Patent ceased through non-payment of renewal fee |